Investments
64Portfolio Exits
5Funds
7Partners & Customers
1About Brandon Capital
Brandon Capital Partners makes seed and venture capital investments to support the development and international growth of Australian life science companies. The firm works collaboratively with entrepreneurs to demonstrate the benefit of their technology, thereby creating value for them, their teams and investors.
Want to inform investors similar to Brandon Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Brandon Capital News
Dec 27, 2022
Dec. 27, 2022 With $20 million raised in a series B round led by Brandon Capital and Tenmile, Aravax Pty Ltd. is poised to begin phase II trials of its immunotherapy, PVX-108, for peanut allergy. “Our product is unlike other approaches that are in later stages of development, and those products generally use natural extracts from peanuts to treat peanut allergy,” Aravax CEO Pascal Hickey told BioWorld.
Brandon Capital Investments
64 Investments
Brandon Capital has made 64 investments. Their latest investment was in Aravax as part of their Series B on December 12, 2022.
Brandon Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
12/19/2022 | Series B | Aravax | $20M | No | Brandon Capital, and Tenmile | 5 |
12/6/2022 | Series A | Entact Bio | $81M | Yes | 11 | |
11/22/2022 | Series C | CatalYm | $51M | Yes | 16 | |
11/9/2022 | Series A | |||||
9/28/2022 | Series A |
Date | 12/19/2022 | 12/6/2022 | 11/22/2022 | 11/9/2022 | 9/28/2022 |
|---|---|---|---|---|---|
Round | Series B | Series A | Series C | Series A | Series A |
Company | Aravax | Entact Bio | CatalYm | ||
Amount | $20M | $81M | $51M | ||
New? | No | Yes | Yes | ||
Co-Investors | Brandon Capital, and Tenmile | ||||
Sources | 5 | 11 | 16 |
Brandon Capital Portfolio Exits
5 Portfolio Exits
Brandon Capital has 5 portfolio exits. Their latest portfolio exit was EBR Systems on November 24, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
11/24/2021 | IPO | Public | 2 | ||
Date | 11/24/2021 | ||||
|---|---|---|---|---|---|
Exit | IPO | ||||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 |
Brandon Capital Fund History
7 Fund Histories
Brandon Capital has 7 funds, including MRCF5.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
4/29/2019 | MRCF5 | $147.67M | 2 | ||
7/26/2016 | Medical Research Commercialization Fund III | ||||
5/20/2015 | Medical Research Commercialisation Fund III | ||||
6/30/2012 | MRCF IIF Partnership LP | ||||
6/30/2009 | Brandon Biosciences Fund No 1 |
Closing Date | 4/29/2019 | 7/26/2016 | 5/20/2015 | 6/30/2012 | 6/30/2009 |
|---|---|---|---|---|---|
Fund | MRCF5 | Medical Research Commercialization Fund III | Medical Research Commercialisation Fund III | MRCF IIF Partnership LP | Brandon Biosciences Fund No 1 |
Fund Type | |||||
Status | |||||
Amount | $147.67M | ||||
Sources | 2 |
Brandon Capital Partners & Customers
1 Partners and customers
Brandon Capital has 1 strategic partners and customers. Brandon Capital recently partnered with COPD Foundation on February 2, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
2/23/2022 | Partner | United States | 1 |
Date | 2/23/2022 |
|---|---|
Type | Partner |
Business Partner | |
Country | United States |
News Snippet | |
Sources | 1 |
Brandon Capital Team
5 Team Members
Brandon Capital has 5 team members, including current Founder, Managing Director, Stephen Thompson.
Name | Work History | Title | Status |
|---|---|---|---|
Stephen Thompson | Terra Rossa Capital, Apax Partners, and Cantab Pharmaceuticals | Founder, Managing Director | Current |
Name | Stephen Thompson | ||||
|---|---|---|---|---|---|
Work History | Terra Rossa Capital, Apax Partners, and Cantab Pharmaceuticals | ||||
Title | Founder, Managing Director | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.